$CRDF Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

#daytrading #daytrader #daytrade #stockstowatch #stocksinnews #trading #trade #trader #stocks #stockmarket #stockmarketnews